A Study to Examine APL-130277 in Patients With Parkinson's Disease

Completed · Phase 2

Conditions studied: Parkinson's Disease

In brief

The primary objective of this study is to evaluate the efficacy, tolerability and safety of single treatments of APL-130277 in 16 patients with Parkinson's Disease (PD)

Key facts

Study ID

NCT02228590

Run by

Sumitomo Pharma America, Inc.

People needed

20

Starts

2014-08-31

Expected to finish

2014-11-24

Last updated by the study team

2020-07-30

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female ≥18 years of age.
• Clinical diagnosis of Idiopathic PD
• Receiving stable doses of L-dopa +/- other adjunctive PD therapy for at least 4 weeks before study participation.
• At least one OFF episode per day and a total daily OFF time of > 2 hours duration.
• Experience predictable OFF episodes in the morning on awakening prior to receiving morning dose of levodopa.
• Stage I to III on the Hoehn and Yahr scale in the "ON" state.
• If female and of childbearing potential, must agree to use one of the following methods of birth control:
• Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the study.
• Able to understand the consent form, and to provide written informed consent.

You may not qualify if…

• Atypical or secondary parkinsonism
• Changes in L-dopa or other PD drug dosing regimens 4 weeks before the screening visit.
• Past treatment with any form of apomorphine within 30 days of Dosing Day 1 (patients who stopped apomorphine for reasons other than lack of efficacy OR tolerability issues may be considered for the trial).
• Female who is pregnant or lactating.
• Contraindications to APOKYN or hypersensitive to apomorphine hydrochloride or any of the ingredients of APOKYN (notably sodium metabisulfite), or Tigan®.
• Participation in any other clinical trial within 14 days of the screening visit.
• Receipt of any investigational (i.e., unapproved) medication within 30 days of the screening visit.
• Currently taking, or likely to need to take at any time during the course of the study
• Currently taking dopamine antagonists or depleting drugs excluding anticholinergics and/or antihistamines with anticholinergic effects.
• Drug or alcohol dependency in the past 6 months.
• Clinically significant orthostatic hypotension.
• Malignant melanoma or a history of previously treated malignant melanoma within 5 years.
• Clinically significant medical surgical or laboratory abnormality in the judgment of the investigator.
• Psychiatric disorder, including but not limited to dementia or any disorder that, in the opinion of the Investigator requires ongoing treatment that would make study participation unsafe or make treatment compliance difficult.
• Dementia that precludes providing informed consent.
• Potential for lack of compliance and follow-up in the judgment of the investigator.
• Any other condition, current therapy, or prior therapy (within 30 days of the screening visit), which, in the opinion of the Investigator, would make the subject unsuitable for the study.
• Previous neurosurgery for PD.
• Donation of blood or plasma in the 30 days prior to dosing.
• Presence of cankers or mouth sores.

Where it is running

• Banner Sun Health Research Institute — Sun City, Arizona, United States
• Rocky Mountain Movement Disorders Center — Englewood, Colorado, United States
• Parkinson's Disease and Movement Disorders Center of Boca Raton — Boca Raton, Florida, United States
• University of South Florida Parkinson's Disease and Movement Disorders Center — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.